Analysts Issue Forecasts for Fractyl Health Q1 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Fractyl Health in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at $0.02 EPS.

GUTS has been the subject of a number of other research reports. Morgan Stanley lowered shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.45 on Friday. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $3.03. The firm’s fifty day simple moving average is $0.71 and its 200 day simple moving average is $1.28. The company has a current ratio of 4.78, a quick ratio of 4.27 and a debt-to-equity ratio of 3.23. The firm has a market capitalization of $71.17 million, a PE ratio of -0.24 and a beta of 1.51.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Fractyl Health in the 4th quarter worth approximately $153,000. Susquehanna Portfolio Strategies LLC bought a new stake in shares of Fractyl Health during the fourth quarter valued at approximately $108,000. Quadrature Capital Ltd raised its stake in shares of Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after purchasing an additional 277,174 shares in the last quarter. Millennium Management LLC lifted its position in Fractyl Health by 356.6% in the fourth quarter. Millennium Management LLC now owns 1,861,418 shares of the company’s stock worth $4,095,000 after purchasing an additional 1,453,751 shares during the period. Finally, Catalio Capital Management LP boosted its stake in Fractyl Health by 5.3% during the fourth quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock worth $12,082,000 after buying an additional 277,630 shares in the last quarter.

Key Stories Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.